{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T08:42:11Z","timestamp":1768898531872,"version":"3.49.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BeiGene funded this study."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01044-4","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T09:02:14Z","timestamp":1714640534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed\/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Mohseninejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swetha","family":"Challagulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhys","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol"},{"key":"1044_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"1044_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR, Lamanna N, O\u2019Brien SM, Tam CS, et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023;41:1035\u201345.","journal-title":"J Clin Oncol"},{"key":"1044_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2217\/fon-2019-0844","volume":"16","author":"P Hillmen","year":"2020","unstructured":"Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O\u2019Brien SM, Qui L, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Future Oncol. 2020;16:517\u201323.","journal-title":"Future Oncol"},{"key":"1044_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health"},{"key":"1044_CR6","doi-asserted-by":"publisher","first-page":"e78258de","DOI":"10.1097\/01.HS9.0000969484.78258.de","volume":"7","author":"P Ghia","year":"2023","unstructured":"Ghia P, Munir T, Burger J, Seymour J, Rogers K, Huang HH, et al. P645 Ibrutinib for treatment of relapsed-refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison of 3 randomized phase 3 trials. Hemasphere. 2023;7:e78258de.","journal-title":"Hemasphere"},{"key":"1044_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"1044_CR8","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","volume":"27","author":"TR Fleming","year":"2009","unstructured":"Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009;27:2874\u201380.","journal-title":"J Clin Oncol"},{"key":"1044_CR9","doi-asserted-by":"crossref","unstructured":"Higgins K, Levin G. Considerations for open-label clinical trials: design, conduct, and analysis. U.S. Food and Drug Administration, 2023 FDA Science Forum. 2023. https:\/\/www.fda.gov\/science-research\/fda-science-forum\/considerations-open-label-clinical-trials-design-conduct-and-analysis.","DOI":"10.1177\/17407745241244788"},{"key":"1044_CR10","unstructured":"PDQ\u00ae Adult Treatment Editorial Board. PDQ chronic lymphocytic leukemia treatment. Bethesda, MD: National Cancer Institute; 2023. https:\/\/www.cancer.gov\/types\/leukemia\/hp\/cll-treatment-pdq."},{"key":"1044_CR11","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0046","volume":"12","author":"A Freitag","year":"2023","unstructured":"Freitag A, Gurskyte L, Sarri G. Increasing transparency in indirect treatment comparisons: is selecting effect modifiers the missing part of the puzzle? A review of methodological approaches and critical considerations. J Comp Eff Res. 2023;12:e230046.","journal-title":"J Comp Eff Res"},{"key":"1044_CR12","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s12325-023-02520-2","volume":"40","author":"T Jiang","year":"2023","unstructured":"Jiang T, Youn B, Paradis AD, Beckerman R, Barnieh L, Johnson NB. A critical appraisal of matching-adjusted indirect comparisons in spinal muscular atrophy. Adv Ther. 2023;40:2985\u20133005.","journal-title":"Adv Ther"},{"key":"1044_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28:935\u201345.","journal-title":"Pharmacoeconomics"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01044-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01044-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T09:02:46Z","timestamp":1714640566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01044-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01044-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MS reports receiving funding from BeiGene paid to Fred Hutchinson Cancer Research Center and the University of Washington (Seattle, WA, USA), with regards to the submitted work; research funding from Pharmacyclics (Inst), Acerta Pharma (Inst), Merck (Inst), TG Therapeutics (Inst), BeiGene (Inst), Celgene (Inst), Genentech (Inst), MustangBio (Inst), AbbVie (Inst), Sunesis Pharmaceuticals (Inst), Bristol Myers Squibb\/Celgene, Genmab (Inst), and Vincerx Pharma (Inst); and consulting or advisory roles with AbbVie, Genentech, AstraZeneca, Sound Biologics, Cellectar, Pharmacyclics, BeiGene, Bristol Myers Squibb\/Celgene, MorphoSys, Innate Pharma, Kite, a Gilead Company, Adaptive Biotechnologies, Epizyme, Fate Therapeutics, Lilly, Regeneron, Adaptimmune, MustangBio, TG Therapeutics, and MEI Pharma, outside the submitted work. AT reports receiving consulting fees from AbbVie, AstraZeneca, BeiGene, and Janssen; and honoraria from AbbVie, AstraZeneca, BeiGene, and Janssen, outside the submitted work. LM, KY, SX, AC, SC, MX, and RW are employees of BeiGene, with regards to the submitted work, and report stocks or stock options, or both, from BeiGene, outside the submitted work. NL reports receiving consulting or advisory roles with Celgene, Genentech, AbbVie, ProNAi, Pharmacyclics, Juno Therapeutics, Roche, Janssen, AstraZeneca, Gilead Sciences, BeiGene, and Loxo\/Lilly Research; and funding from Genentech\/AbbVie (Inst), Infinity Pharmaceuticals (Inst), Gilead Sciences (Inst), ProNAi (Inst), BeiGene (Inst), Verastem (Inst), Juno Therapeutics (Inst), TG Therapeutics (Inst), Acerta Pharma\/AstraZeneca (Inst), Loxo (Inst), Oncternal Therapeutics, Inc (Inst), MingSight (Inst), and Octapharm (Inst), outside the submitted work. SMO reports employment with University of California, Irvine; honoraria from Celgene, Janssen, Pharmacyclics, Gilead Sciences, Pfizer, Amgen, Astellas Pharma, GlaxoSmithKline, Aptose Biosciences, Vaniam Group, AbbVie, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Eisai, TG Therapeutics, and NOVA Research Company; consulting or advisory roles with Amgen, Celgene, GlaxoSmithKline, Janssen Oncology, Aptose Biosciences, Vaniam Group, AbbVie\/Genentech, Sunesis Pharmaceuticals, Alexion Pharmaceuticals, Astellas Pharma, Gilead Sciences, Pharmacyclics, TG Therapeutics, Pfizer, and Sunesis Pharmaceuticals; receiving research funding from Acerta Pharma (Inst), Regeneron (Inst), Gilead Sciences (Inst), Pfizer (Inst), TG Therapeutics (Inst), Pharmacyclics (Inst), Kite, a Gilead Company (Inst), Sunesis Pharmaceuticals (Inst), Lilly (Inst), and Caribou Biosciences (Inst); and travel, accommodations, expenses from Celgene, Janssen, Gilead Sciences, Regeneron, and Janssen Oncology. JB reports receiving research funding from BeiGene (Inst), Gilead Sciences (Inst), Loxo\/Lilly (Inst), MEI Pharma (Inst), Secura Bio (Inst), Sun Pharma (Inst), and TG Therapeutics (Inst); and consulting or advisory roles with AbbVie, Acerta\/AstraZeneca, BeiGene, Bristol Myers Squibb\/Celgene\/Juno, Catapult Therapeutics, Lilly, Genentech\/Roche, HUTCHMED, iOnctura, Janssen, MEI Pharma, MorphoSys, Novartis, and Pharmacyclics, outside of the submitted work. CT reports receiving funding from Janssen-Cilag (Inst), AbbVie (Inst), BeiGene (Inst); consulting or advisory roles with Janssen, Loxo, Roche, BeiGene, and AbbVie; and honoraria from Janssen-Cilag, AbbVie, Novartis, BeiGene, Pharmacyclics, Roche\/Genentech, and Loxo\/Lilly, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}